MTOR and cancer: Inhibition of Wnt/β-catenin and phosphatidylinositol 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathways is considered a possible innovative therapeutic strategy for cancer treatment [109,110].